E
Excaliard Pharmaceuticals
Biotechnology company developing antisense drugs for the local treatment of scarring and other fibrotic diseases
About Excaliard Pharmaceuticals
Excaliard Pharmaceuticals, Inc. operated as a biopharmaceutical company with a specific focus on developing treatments for skin fibrosis, commonly known as scarring. Founded in 2006 by Nicholas Dean, the company established itself to address the market for skin scarring and other fibrotic disorders. One of the company's co-founders, J. Gordon Foulkes, also served as CEO and was a managing director at RiverVest Venture Partners, one of the venture capital firms that provided initial funding.
The company's business model centered on the development and eventual commercialization of novel drugs. Excaliard operated on a virtual model with a small number of full-time employees, outsourcing a significant portion of its operations. This lean structure was supported by a single Series A funding round of $15.5 million in 2007 from investors including Alta Partners, ProQuest Investments, and RiverVest Venture Partners. A key part of its strategy involved a partnership with Isis Pharmaceuticals (now Ionis Pharmaceuticals), from which it licensed the core antisense technology for its lead product candidate.
Excaliard’s primary asset was EXC 001, an antisense oligonucleotide drug candidate designed to treat skin scarring. The product works by inhibiting the expression of Connective Tissue Growth Factor (CTGF), a protein that is over-expressed in damaged tissue and contributes to the formation of disfiguring scars. The potential market for such a treatment is substantial, covering scarring from millions of surgical procedures performed annually. After demonstrating positive results in Phase II clinical trials for reducing scar severity, Excaliard became an attractive acquisition target. In late 2011, Pfizer Inc. announced its acquisition of Excaliard, a deal completed in December of that year for an undisclosed sum involving an upfront payment and future milestone-based payments. The acquisition allowed Pfizer to integrate EXC 001 into its R&D pipeline to address the unmet need for an FDA-approved treatment for excessive skin scarring.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITION✓Exit | Nov 2011 | $0 | — | Pfizer | — |
| SERIES A✓Equity / VC | Nov 2007 | $16M | $62M | Alta Partners · RiverVest Venture Partners · ProQuest Investments | — |
Growth signals
Latest recorded traffic for Excaliard Pharmaceuticals is 380 monthly website visits, up 660% over the last three months. Excaliard Pharmaceuticals's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Excaliard Pharmaceuticals in the Carlsbad ecosystem
The Excaliard Pharmaceuticals office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
Alta Partners
RiverVest Venture Partners- PIProQuest Investments
Other known investors1 additional known investor
Pfizer
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Excaliard Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Excaliard Pharmaceuticals’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









